Clinical Trial Update: Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating inhibition of the Bradykinin B2 receptor to prevent intradialytic hypotension is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intradialytic Hypotension

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Intradialytic Hypotension | Phase 3 | Status: RECRUITING